Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

EKF Diagnostics Welcomes NICE Guidelines for Diabetes Prevention

Published: Thursday, August 16, 2012
Last Updated: Thursday, August 16, 2012
Bookmark and Share
Quo-Test and Quo-Lab HbA1c blood analyzers ideal tools to identify high risk patients.

EKF Diagnostics welcomes the recent release of a public health guidance document to prevent the development of type 2 diabetes in high risk individuals.

“Preventing type 2 diabetes: risk identification and interventions for individuals at high risk” sets out recommendations that include the use of glycated haemoglobin (HbA1c) testing to manage the disease, a particular speciality of EKF Diagnostics, a worldwide manufacturer of near patient analyzers.

The guidelines, written by the UK’s National Institute for Health and Clinical Excellence (NICE), and commissioned by the UK Department of Health, gives recommendations to health care providers for developing a two-stage strategy to identify people at high risk of type 2 diabetes (and those with undiagnosed type 2 diabetes).

The strategy consists of a risk assessment, followed, where necessary, by a blood test to confirm whether people have the disease, or are at high risk of developing it.

Those at high risk are to be provided with a programme to help implement healthy lifestyle changes that prevent or delay the onset of the disease.

The report follows the World Health Organization (WHO) recommendations that glycated haemoglobin (HbA1c) can be used as an alternative to standard glucose measures to diagnose type 2 diabetes among non-pregnant adults.

The benefits of HbA1c measurement, compared to fasting glucose testing, include the convenience for patients, since there is no requirement to fast for a 12-hour period prior to testing.

HbA1c measurements can be easily, reliably and rapidly carried out by EKF’s Quo-Test and Quo-Lab near patient analyzers. For example, fast and accurate results are obtained from the analyzer in just four minutes from 4μl of blood from finger prick or venous sample.

The analyzers are also able to produce accurate quantitative results enabling a clear distinction of the level of risk (WHO has determined that HbA1c levels of 48 mmol/mol (6.5%) or above indicate that someone has type 2 diabetes), and a UK expert group has recognized that there is a continuum of risk across a range of subdiabetic HbA1c levels - so that people with an HbA1c below 42 mmol/mol (6.0%) may also be at risk).

EKF Diagnostics CEO Julian Baines supported the NICE release stating “EKF Diagnostics welcomes the release of the NICE guidance, particularly the recognition that HbA1c can be used in identifying adults at risk of diabetes. The Quo-Test and Quo-Lab range of HbA1c analyzers will greatly aid UK health providers in identifying at risk individuals and monitoring disease and treatment status in patients who are diagnosed with diabetes.”

Baines further commented that “The certified accuracy and ease of use of the Quo-Test and Quo-Lab analyzers will allow care providers to rapidly establish preventative treatment programmes for at risk individuals. This rapid intervention reduces overall treatment costs, because in many at risk cases, simple life style changes, to diet or physical activity levels for example, are sufficient to reduce the chances of disease onset.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

EKF Diagnostics’ Growth Drives New Role Creation
Expanding business welcomes new faces to further strengthen IVD expertise and new product development.
Saturday, July 18, 2015
EKF Diagnostics Collaborates with Joslin Diabetes Center
Supporting the ongoing clinical and commercial development of early Diabetic Kidney Disease biomarkers.
Monday, November 17, 2014
Studies Validate EKF Diagnostics’ Early Stage Test for Progressive DKD
Independent scientific evidence confirms novel sTNFR1/2 biomarkers can accurately predict end-stage renal disease, up to 10 years in advance.
Friday, May 23, 2014
New Clinical Diagnostics Distributor Program Enhances EKF Customer Service
EKF Diagnostics appoints Simona Carnielli as new EMEA Distribution Manager.
Thursday, May 08, 2014
EKF Diagnostics Acquires Selah Genomics and DiaSpect Medical
Combined with the recent acquisition of Seperation Technology the purchases strengthen EKF’s product and services offering.
Tuesday, April 22, 2014
EKF Diagnostics Acquires Separation Technology
Acquisition complements EKF’s existing offering in the hemoglobin testing market place.
Thursday, March 27, 2014
PointMan™ Enriches Low-level DNA Mutations from Whole Blood
Ultra-sensitive PointMan™ enables blood sampling instead of tissue biopsies for cancer patient mutation status assessment.
Wednesday, January 22, 2014
Scientific News
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Biomedical Imaging at One-Thousandth the Cost
Mathematical modeling enables $100 depth sensor to approximate the measurements of a $100,000 piece of lab equipment.
Improving Outcomes for Lung Cancer and Diabetic Patients
Novel technologies have been developed with support from SBRI Healthcare funding.
New Way of Detecting Cancer
A new RNA test of blood platelets can be used to detect, classify and pinpoint the location of cancer by analysing a sample equivalent to one drop of blood.
Rapid, Portable Ebola Diagnostic
Scientists confirmed the efficiency of the novel Ebola detection method in field trials.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Blood Test Picks Out Prostate Cancer Drug Resistance
Scientists have developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug, and identify in advance patients who will not respond to treatment.
Antibody Targets Key Cancer Marker
University of Wisconsin-Madison researchers have created a molecular structure that attaches to a molecule on highly aggressive brain cancer and causes tumors to light up in a scanning machine.
Key Piece of MRSA Vaccine Puzzle
New research funded by the Health Research Board and the Wellcome Trust has pinpointed immune cells that could be targeted by an MRSA vaccine.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos